MktsMarkets

Lexaria Bioscience Corp.
NASDAQ: LEXXKey statistics
LEXX News
Stories mentioning LEXX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Feb 28 | Q4 '25Nov 30 | Q3 '25Aug 31 | Q2 '25May 31 | Q1 '25Feb 28 | Q4 '24Nov 30 | Q3 '24Aug 31 | Q2 '24May 31 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 20.00 | 0.00 | 174.00 | 174.00 | 174.00 | 184.00 | 84.00 | 84.00 |
| Cost of Goods Sold | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 |
| Gross Profit | 20.00 | 0.00 | 174.00 | 174.00 | 174.00 | 181.00 | 84.00 | 84.00 |
| Operating Expenses | ||||||||
| Research & Development | 475.00 | 671.00 | 1,882 | 2,718 | 1,686 | 1,953 | 968.00 | 573.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 1,472 | 1,574 | 2,863 | 3,924 | 2,925 | 2,872 | 2,287 | 1,827 |
| Operating Income (Loss) | (1,452) | (1,574) | (2,689) | (3,750) | (2,751) | (2,691) | (2,203) | (1,743) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (16.00) | 16.00 | (41.00) | |||||
| Pretax Income | ||||||||
| Tax Provision | 3.00 | 2.00 | 0.00 | 0.00 | ||||
| Net Income (Loss) | (1,450) | (1,595) | (2,696) | (3,789) | (2,713) | (2,704) | (2,184) | (1,782) |
| Earnings Per Share (Basic) | ||||||||
| Earnings Per Share (Diluted) | (0.06) | (0.07) | (0.15) | (0.21) | (0.15) | (0.16) | (0.18) | (0.13) |
| Weighted Average Shares Outstanding (Basic) | ||||||||
| Weighted Average Shares Outstanding (Diluted) | 24,444 | 21,376 | 17,999 | 18,298 | 17,512 | 16,669 | 12,384 | 13,855 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About LEXX
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a stock listed on the Nasdaq Stock Market under the ticker symbol LEXX. It last traded at $3.49 (Oct 30, 2026, 4:00 PM ET), down 7.4% on the day. That gives Lexaria Bioscience a market capitalisation of $7.4M.
Over the past 52 weeks LEXX has traded between $2.43 and $21.60.
Revenue for the quarter ended Feb 28, 2026 was $20.0K; a net loss of $1.5M. Revenue was down 88.5% from $174.0K in the quarter ended Feb 28, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Feb 28, 2026 | $20.0K | -$1.5M | -7250.0% |
| Nov 30, 2025 | $0 | -$1.6M | — |
| Aug 31, 2025 | $174.0K | -$2.7M | -1549.4% |
| May 31, 2025 | $174.0K | -$3.8M | -2177.6% |
From Lexaria Bioscience’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…